Perigon Wealth Management LLC cut its holdings in Pfizer Inc. (NYSE:PFE) by 3.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,728 shares of the biopharmaceutical company’s stock after selling 627 shares during the quarter. Perigon Wealth Management LLC’s holdings in Pfizer were worth $514,000 at the end of the most recent quarter.
Other large investors have also made changes to their positions in the company. Reik & CO. LLC raised its position in Pfizer by 1.4% in the 1st quarter. Reik & CO. LLC now owns 19,160 shares of the biopharmaceutical company’s stock worth $625,000 after buying an additional 265 shares during the last quarter. Aevitas Wealth Management Inc. boosted its stake in shares of Pfizer by 1.7% during the 2nd quarter. Aevitas Wealth Management Inc. now owns 15,916 shares of the biopharmaceutical company’s stock worth $520,000 after acquiring an additional 269 shares during the last quarter. Windsor Capital Management LLC grew its position in shares of Pfizer by 1.6% during the 1st quarter. Windsor Capital Management LLC now owns 17,991 shares of the biopharmaceutical company’s stock valued at $587,000 after acquiring an additional 276 shares during the period. GYL Financial Synergies LLC grew its position in shares of Pfizer by 0.9% during the 1st quarter. GYL Financial Synergies LLC now owns 30,718 shares of the biopharmaceutical company’s stock valued at $1,003,000 after acquiring an additional 283 shares during the period. Finally, Gilbert & Cook Inc. raised its holdings in Pfizer by 3.0% in the 1st quarter. Gilbert & Cook Inc. now owns 9,794 shares of the biopharmaceutical company’s stock worth $320,000 after purchasing an additional 285 shares during the period. 70.20% of the stock is currently owned by hedge funds and other institutional investors.
Several research firms have recently commented on PFE. SVB Leerink raised their price objective on Pfizer from $39.00 to $42.00 and gave the stock a “market perform” rating in a research note on Wednesday. UBS Group lifted their price target on shares of Pfizer from $37.00 to $39.00 and gave the company a “neutral” rating in a report on Wednesday. Barclays dropped their price target on shares of Pfizer from $37.00 to $35.00 in a research report on Monday, June 1st. Morgan Stanley lifted their target price on shares of Pfizer from $36.00 to $42.00 and gave the company an “equal weight” rating in a research note on Thursday. Finally, JPMorgan Chase & Co. cut their price objective on Pfizer from $37.00 to $36.00 and set a “neutral” rating for the company in a research report on Monday, June 1st. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $38.95.
PFE opened at $38.48 on Friday. The company has a quick ratio of 0.78, a current ratio of 1.02 and a debt-to-equity ratio of 0.56. The firm has a market cap of $213.75 billion, a P/E ratio of 15.27, a P/E/G ratio of 3.12 and a beta of 0.68. The business has a fifty day simple moving average of $34.75 and a 200-day simple moving average of $35.79. Pfizer Inc. has a 52 week low of $27.88 and a 52 week high of $40.97.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, July 28th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.64 by $0.14. Pfizer had a net margin of 28.80% and a return on equity of 25.10%. The company had revenue of $11.80 billion for the quarter, compared to the consensus estimate of $11.55 billion. During the same period last year, the firm posted $0.80 EPS. Pfizer’s revenue for the quarter was down 11.0% on a year-over-year basis. Sell-side analysts expect that Pfizer Inc. will post 2.89 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 31st will be given a $0.38 dividend. The ex-dividend date of this dividend is Thursday, July 30th. This represents a $1.52 annualized dividend and a dividend yield of 3.95%. Pfizer’s dividend payout ratio is presently 51.53%.
In related news, SVP Jennifer B. Damico sold 2,181 shares of Pfizer stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $36.13, for a total transaction of $78,799.53. Following the completion of the sale, the senior vice president now owns 7,542 shares in the company, valued at approximately $272,492.46. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.08% of the stock is owned by corporate insiders.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
See Also: What are Institutional Investors?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.